Współistnienie cukrzycy typu 2 oraz przewlekłej niewydolności serca – nieprzypadkowe skojarzenie Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2020
Słowa kluczowe:
niewydolność serca, cukrzyca, glikemia, hemoglobina glikowana, farmakoterapia, otyłość
##plugins.themes.bootstrap3.article.main##
Abstrakt
W ostatnich latach u coraz większej liczby pacjentów dochodzi do współistnienia cukrzycy typu 2 z przewlekłą niewydolnością serca. Ma to bardzo niekorzystny wpływ na rokowanie i wymaga rozważnego planowania terapii uwzględniającego stan danego pacjenta, w tym obecność innych schorzeń. Szczególną uwagę należy zwrócić na obecność przewlekłej choroby nerek, która wpływa na dawkowanie i działanie wielu preparatów. Ważnym aspektem stosowanej terapii jest podwyższone ryzyko hipoglikemii. Trzeba także pamiętać, że cele terapii w tej grupie są nieco inne niż w populacji ogólnej. W zaleceniach ESC w terapii cukrzycy typu 2 u osób z podwyższonym ryzykiem rozwoju niewydolności serca na pierwszy plan wysuwa się nowa grupa leków hipoglikemizujących inhibitory SGLT-2 (empagliflozyna, kanagliflozyna, dapagliflozyna), które zmniejszają częstość hospitalizacji z powodu niewydolności serca o 32–35%. U pacjentów z już istniejącą niewydolnością i cukrzycą metody leczenia nie różnią się od stosowanych w populacji bez cukrzycy typu 2.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Załuska , R., & Grabowski , M. (2020). Współistnienie cukrzycy typu 2 oraz przewlekłej niewydolności serca – nieprzypadkowe skojarzenie. Kardiologia W Praktyce, 14(1-2), 45-51. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1175
Numer
Dział
Medycyna metaboliczna
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017; 3(1): 7-11. http://doi.org/10.15420/cfr.2016:25:2.
2. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators [published correction appears in Lancet. 2017; 389: e1]. Lancet. 2016; 388(10053): 1545-602. http://doi.org/10.1016/S0140-6736(16)31678-6.
3. From AM, Leibson CL, Bursi F et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006; 119(7): 591-9. http://doi.org/ 10.1016/j.amjmed.2006.05.024.
4. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996; 77(11): 1017-20.
5. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe, part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 249(5): 442-63.
6. Dei Cas A, Fonarow GC, Gheorghiade M et al. Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol. 2015; 40(1): 7-43. http://doi.org/10.1016/j.cpcardiol.2014.09.002.
7. Sandesara PB, O’Neal WT, Kelli HM et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care. 2018; 41: 150-5. http://doi.org/10.2337/dc17-0755.
8. Nichols GA, Gullion CM, Koro CE et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004; 27(8): 1879-84.
9. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004; 27(3): 699-703.
10. Boonman-de Winter LJ, Rutten FH, Cramer MJ et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012; 55(8): 2154-62. http://doi.org/10.1007/s00125-012-2579-0.
11. Thrainsdottir IS, Aspelund T, Thorgeirsson G et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005; 28(3): 612-6.
12. van Melle JP, Bot M, de Jonge P et al. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the Heart and Soul Study. Diabetes Care. 2010; 33(9): 2084-9. http://doi.org/10.2337/dc10-0286.
13. Iribarren C, Karter AJ, Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103(22): 2668-73.
14. Pazin-Filho A, Kottgen A, Bertoni AG et al. HbA1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008; 51(12): 2197-204. http://doi.org/10.1007/s00125-008-1164-z.
15. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258): 405-12.
16. Bibbins-Domingo K, Lin F, Vittinghoff E et al. Predictors of heart failure among women with coronary disease. Circulation. 2004; 110: 1424-30. http://doi.org/10.1161/01.CIR. 0000141726.01302.83.
17. Scirica BM, Braunwald E, Raz I et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial [published correction appears in Circulation. 2015;132:e198]. Circulation. 2014; 130(18): 1579-88. http://doi.org/10.1161/CIRCULATIONAHA.114.010389.
18. Devereux RB, Roman MJ, Paranicas M et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation. 2000; 101(19): 2271-6.
19. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006; 48(8): 1548-51. http://doi.org/10.1016/j.jacc.2006.07.033.
20. Palmieri V, Bella JN, Arnett DK et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001; 103(1): 102-7.
21. Rutter MK, Parise H, Benjamin EJ et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003; 107(3): 448-54.
22. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study [published correction appears in J Am Coll Cardiol. 2010; 56: 1612]. J Am Coll Cardiol. 2010; 55(4): 300-5. http://doi.org/10.1016/j.jacc.2009.12.003.
23. Swoboda PP, McDiarmid AK, Erhayiem B et al. Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc. 2017; 6(7): e005539. http://doi.org/10.1161/JAHA.117.005539.
24. Wang TJ, Evans JC, Benjamin EJ et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108(8): 977-82. http://doi.org/10.1161/01.CIR.0000085166.44904.79.
25. Wang TJ, Levy D, Benjamin EJ et al. The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med. 2003; 138(11): 907-16.
26. Paolillo S, Rengo G, Pellegrino T et al. Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. Eur Heart J Cardiovasc Imaging. 2015; 16(10): 1148-53. http://doi.org/10.1093/ehjci/jev061.
27. Fang ZY, Yuda S, Anderson V et al. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol. 2003; 41(4): 611-17.
28. Dunlay SM, Redfield MM, Weston SA et al. Hospitalizations after heart failure diagnosis: a community perspective. J Am Coll Cardiol. 2009; 54(18): 1695-702. http://doi.org/10.1016/j.jacc.2009.08.019.
29. Chaudhry SI, McAvay G, Chen S et al. Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. J Am Coll Cardiol. 2013; 61(6): 635-42. http://doi.org/10.1016/j.jacc.2012.11.027.
30. Lawson CA, Jones PW, Teece L et al. Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic glycemic control and medication intensification. JACC Heart Fail. 2018; 6(1): 18-26. http://doi.org/10.1016/j.jchf.2017.08.020.
31. Castagno D, Baird-Gunning J, Jhund PS et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J. 2011; 162(5): 938-48.e2. http://doi.org/10.1016/j.ahj.2011.07.030.
32. Elder DH, Singh JS, Levin D et al. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail. 2016; 18(1): 94-102. http://doi.org/10.1002/ejhf.455.
33. Selvin E, Rawlings AM, Lutsey PL et al. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation. 2015; 132(4): 269-77. http://doi.org/10.1161/CIRCULATIONAHA.115.015415.
34. Aguilar D, Bozkurt B, Ramasubbu K et al. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009; 54(5): 422-8. http://doi.org/10.1016/j.jacc.2009.04.049.
35. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J. 2006; 151(1): 91. http://doi.org/10.1016/j.ahj.2005.10.008.
36. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117-28.
37. Mahaffey KW, Neal B, Perkovic V et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018; 137(4): 323-34.
38. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347-57.
39. Vermes E, Ducharme A, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003; 107(9): 1291-6.
40. Yusuf S, Ostergren JB, Gerstein HC et al. on behalf of the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure [published correction appears in Circulation. 2005; 112: e292]. Circulation. 2005; 112(1): 48-53. http://doi.org/10.1161/CIRCULATIONAHA.104.528166.
41. Seferovic JP, Claggett B, Seidelmann SB et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017; 5(5): 333-40. http://doi.org/10.1016/S2213-8587(17)30087-6.
42. Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today Ther Strategies. 2012; 9(4): e131-e9.
43. Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am Heart J. 2010; 160(5): 915-21. http://doi.org/10.1016/j.ahj.2010.04.024.
44. Ferrua S, Bobbio M, Catalano E et al. Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? J Card Fail. 2005; 11(8): 590-4. http://doi.org/10.1016/j.cardfail.2005.06.431.
45. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010; 26(3): 615-29. http://doi.org/10.1185/03007990903533681.
46. Wai B, Kearney LG, Hare DL et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012; 11: 14. http://doi.org/10.1186/1475-2840-11-14.
47. Torp-Pedersen C, Metra M, Charlesworth A et al. COMET Investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007; 93(8): 968-73. http://doi.org/10.1136/hrt.2006.092379.
48. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577-89. http://doi.org/10.1056/NEJMoa0806470.
49. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72. http://doi.org/10.1056/NEJMoa0802987.
50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999; 354 (9178): 602]. Lancet. 1998; 352(9131): 837-53.
51. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998; 352(9139): 1558]. Lancet. 1998; 352(9131): 854-65.
52. Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016; 9(5): 504-12. http://doi.org/10.1161/CIRCOUTCOMES.116.002901.
53. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545-59. http://doi.org/10.1056/NEJMoa0802743.
54. Hayward RA, Reaven PD, Wiitala WL et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes [published correction appears in N Engl J Med. 2015;373:198]. N Engl J Med. 2015; 372(23): 2197-206. http://doi.org/10.1056/NEJMoa1414266.
55. Holman RR, Bethel MA, Mentz RJ et al. Effects of once‑weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228-39.
56. Marso SP, Daniels GH, Brown‑Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311-22.
57. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373: 2247-57.
58. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834-44.
59. Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381(9): 841-51. http://doi.org/10.1056/ NEJMoa1901118.
60. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑controlled trial. Lancet. 2019; 394(10193): 121-30.
61. Jorsal A, Kistorp C, Holmager P et al. Effect of liraglutide, a glucagon‑like peptide‑1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double-blind, randomised, placebo‑controlled trial. Eur J Heart Fail. 2017; 19: 69-77.
62. Margulies KB, Hernandez AF, Redfield MM et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016; 316(5): 500-8.
63. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232-42.
64. Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 321(1): 69-79.
65. Smooke S, Horwich TB, Fonarow GC. Insulin‑treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005; 149(1): 168-74.
66. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): 1279-89.
67. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368: 1096-105.
68. Hernandez AV, Usmani A, Rajamanickam A et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta‑analysis and meta‑regression analysis of placebo‑controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011; 11(2): 115-28.
69. Home PD, Pocock SJ, Beck‑Nielsen H et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RE‑CORD): a multicentre, randomised, open‑label trial. Lancet. 2009; 373(9681): 2125-35.
2. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators [published correction appears in Lancet. 2017; 389: e1]. Lancet. 2016; 388(10053): 1545-602. http://doi.org/10.1016/S0140-6736(16)31678-6.
3. From AM, Leibson CL, Bursi F et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006; 119(7): 591-9. http://doi.org/ 10.1016/j.amjmed.2006.05.024.
4. Shindler DM, Kostis JB, Yusuf S et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996; 77(11): 1017-20.
5. Cleland JG, Swedberg K, Follath F et al. The EuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe, part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 249(5): 442-63.
6. Dei Cas A, Fonarow GC, Gheorghiade M et al. Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol. 2015; 40(1): 7-43. http://doi.org/10.1016/j.cpcardiol.2014.09.002.
7. Sandesara PB, O’Neal WT, Kelli HM et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care. 2018; 41: 150-5. http://doi.org/10.2337/dc17-0755.
8. Nichols GA, Gullion CM, Koro CE et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004; 27(8): 1879-84.
9. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004; 27(3): 699-703.
10. Boonman-de Winter LJ, Rutten FH, Cramer MJ et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012; 55(8): 2154-62. http://doi.org/10.1007/s00125-012-2579-0.
11. Thrainsdottir IS, Aspelund T, Thorgeirsson G et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care. 2005; 28(3): 612-6.
12. van Melle JP, Bot M, de Jonge P et al. Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the Heart and Soul Study. Diabetes Care. 2010; 33(9): 2084-9. http://doi.org/10.2337/dc10-0286.
13. Iribarren C, Karter AJ, Go AS et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001; 103(22): 2668-73.
14. Pazin-Filho A, Kottgen A, Bertoni AG et al. HbA1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008; 51(12): 2197-204. http://doi.org/10.1007/s00125-008-1164-z.
15. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258): 405-12.
16. Bibbins-Domingo K, Lin F, Vittinghoff E et al. Predictors of heart failure among women with coronary disease. Circulation. 2004; 110: 1424-30. http://doi.org/10.1161/01.CIR. 0000141726.01302.83.
17. Scirica BM, Braunwald E, Raz I et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial [published correction appears in Circulation. 2015;132:e198]. Circulation. 2014; 130(18): 1579-88. http://doi.org/10.1161/CIRCULATIONAHA.114.010389.
18. Devereux RB, Roman MJ, Paranicas M et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation. 2000; 101(19): 2271-6.
19. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006; 48(8): 1548-51. http://doi.org/10.1016/j.jacc.2006.07.033.
20. Palmieri V, Bella JN, Arnett DK et al. Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension Genetic Epidemiology Network (HyperGEN) study. Circulation. 2001; 103(1): 102-7.
21. Rutter MK, Parise H, Benjamin EJ et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003; 107(3): 448-54.
22. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study [published correction appears in J Am Coll Cardiol. 2010; 56: 1612]. J Am Coll Cardiol. 2010; 55(4): 300-5. http://doi.org/10.1016/j.jacc.2009.12.003.
23. Swoboda PP, McDiarmid AK, Erhayiem B et al. Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. J Am Heart Assoc. 2017; 6(7): e005539. http://doi.org/10.1161/JAHA.117.005539.
24. Wang TJ, Evans JC, Benjamin EJ et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003; 108(8): 977-82. http://doi.org/10.1161/01.CIR.0000085166.44904.79.
25. Wang TJ, Levy D, Benjamin EJ et al. The epidemiology of “asymptomatic” left ventricular systolic dysfunction: implications for screening. Ann Intern Med. 2003; 138(11): 907-16.
26. Paolillo S, Rengo G, Pellegrino T et al. Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. Eur Heart J Cardiovasc Imaging. 2015; 16(10): 1148-53. http://doi.org/10.1093/ehjci/jev061.
27. Fang ZY, Yuda S, Anderson V et al. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol. 2003; 41(4): 611-17.
28. Dunlay SM, Redfield MM, Weston SA et al. Hospitalizations after heart failure diagnosis: a community perspective. J Am Coll Cardiol. 2009; 54(18): 1695-702. http://doi.org/10.1016/j.jacc.2009.08.019.
29. Chaudhry SI, McAvay G, Chen S et al. Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. J Am Coll Cardiol. 2013; 61(6): 635-42. http://doi.org/10.1016/j.jacc.2012.11.027.
30. Lawson CA, Jones PW, Teece L et al. Association between type 2 diabetes and all-cause hospitalization and mortality in the UK general heart failure population: stratification by diabetic glycemic control and medication intensification. JACC Heart Fail. 2018; 6(1): 18-26. http://doi.org/10.1016/j.jchf.2017.08.020.
31. Castagno D, Baird-Gunning J, Jhund PS et al. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J. 2011; 162(5): 938-48.e2. http://doi.org/10.1016/j.ahj.2011.07.030.
32. Elder DH, Singh JS, Levin D et al. Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. Eur J Heart Fail. 2016; 18(1): 94-102. http://doi.org/10.1002/ejhf.455.
33. Selvin E, Rawlings AM, Lutsey PL et al. Fructosamine and glycated albumin and the risk of cardiovascular outcomes and death. Circulation. 2015; 132(4): 269-77. http://doi.org/10.1161/CIRCULATIONAHA.115.015415.
34. Aguilar D, Bozkurt B, Ramasubbu K et al. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009; 54(5): 422-8. http://doi.org/10.1016/j.jacc.2009.04.049.
35. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J. 2006; 151(1): 91. http://doi.org/10.1016/j.ahj.2005.10.008.
36. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117-28.
37. Mahaffey KW, Neal B, Perkovic V et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018; 137(4): 323-34.
38. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347-57.
39. Vermes E, Ducharme A, Bourassa MG et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003; 107(9): 1291-6.
40. Yusuf S, Ostergren JB, Gerstein HC et al. on behalf of the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure [published correction appears in Circulation. 2005; 112: e292]. Circulation. 2005; 112(1): 48-53. http://doi.org/10.1161/CIRCULATIONAHA.104.528166.
41. Seferovic JP, Claggett B, Seidelmann SB et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017; 5(5): 333-40. http://doi.org/10.1016/S2213-8587(17)30087-6.
42. Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today Ther Strategies. 2012; 9(4): e131-e9.
43. Yamaji M, Tsutamoto T, Kawahara C et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am Heart J. 2010; 160(5): 915-21. http://doi.org/10.1016/j.ahj.2010.04.024.
44. Ferrua S, Bobbio M, Catalano E et al. Does carvedilol impair insulin sensitivity in heart failure patients without diabetes? J Card Fail. 2005; 11(8): 590-4. http://doi.org/10.1016/j.cardfail.2005.06.431.
45. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010; 26(3): 615-29. http://doi.org/10.1185/03007990903533681.
46. Wai B, Kearney LG, Hare DL et al. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012; 11: 14. http://doi.org/10.1186/1475-2840-11-14.
47. Torp-Pedersen C, Metra M, Charlesworth A et al. COMET Investigators. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007; 93(8): 968-73. http://doi.org/10.1136/hrt.2006.092379.
48. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577-89. http://doi.org/10.1056/NEJMoa0806470.
49. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72. http://doi.org/10.1056/NEJMoa0802987.
50. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999; 354 (9178): 602]. Lancet. 1998; 352(9131): 837-53.
51. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998; 352(9139): 1558]. Lancet. 1998; 352(9131): 854-65.
52. Rodríguez-Gutiérrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016; 9(5): 504-12. http://doi.org/10.1161/CIRCOUTCOMES.116.002901.
53. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545-59. http://doi.org/10.1056/NEJMoa0802743.
54. Hayward RA, Reaven PD, Wiitala WL et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes [published correction appears in N Engl J Med. 2015;373:198]. N Engl J Med. 2015; 372(23): 2197-206. http://doi.org/10.1056/NEJMoa1414266.
55. Holman RR, Bethel MA, Mentz RJ et al. Effects of once‑weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228-39.
56. Marso SP, Daniels GH, Brown‑Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311-22.
57. Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373: 2247-57.
58. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834-44.
59. Husain M, Birkenfeld AL, Donsmark M et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019; 381(9): 841-51. http://doi.org/10.1056/ NEJMoa1901118.
60. Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double‑blind, randomised placebo‑controlled trial. Lancet. 2019; 394(10193): 121-30.
61. Jorsal A, Kistorp C, Holmager P et al. Effect of liraglutide, a glucagon‑like peptide‑1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double-blind, randomised, placebo‑controlled trial. Eur J Heart Fail. 2017; 19: 69-77.
62. Margulies KB, Hernandez AF, Redfield MM et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016; 316(5): 500-8.
63. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373: 232-42.
64. Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019; 321(1): 69-79.
65. Smooke S, Horwich TB, Fonarow GC. Insulin‑treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005; 149(1): 168-74.
66. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): 1279-89.
67. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368: 1096-105.
68. Hernandez AV, Usmani A, Rajamanickam A et al. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta‑analysis and meta‑regression analysis of placebo‑controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011; 11(2): 115-28.
69. Home PD, Pocock SJ, Beck‑Nielsen H et al; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RE‑CORD): a multicentre, randomised, open‑label trial. Lancet. 2009; 373(9681): 2125-35.